Skip to main content
Clinical Trials/NCT06771817
NCT06771817
Recruiting
Not Applicable

Feasibility and Preliminary Effectiveness of Written Exposure Therapy (WET) for Pregnant or Postpartum Adolescents and Youth With Post-Traumatic Stress Disorder (PTSD) in an Open Pilot Trial

University of Texas Southwestern Medical Center1 site in 1 country30 target enrollmentMarch 26, 2025

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Post-Traumatic Stress Disorder in Adolescence
Sponsor
University of Texas Southwestern Medical Center
Enrollment
30
Locations
1
Primary Endpoint
Feasibility of Written Exposure Therapy
Status
Recruiting
Last Updated
last year

Overview

Brief Summary

This is a feasibility and acceptability study of Written Exposure Therapy (WET) for PTSD in pregnant and postpartum adolescents and youth with PTSD.

Detailed Description

The main goal of this research study is to investigate whether a short trauma-focused therapy involving writing is something teens and young adults who are pregnant or recently had a baby and have symptoms related to post-traumatic stress disorder (PTSD) are able to complete. This study is specifically examining the feasibility and acceptability of Written Exposure Therapy (WET) as a treatment in this population. WET is a type of therapy where people write about a traumatic experience they have gone through, and their feelings about the event. Doing this over several sessions may help some people reduce how distressing the memory is to them over time. In addition, this study aims to investigate if WET can reduce symptoms related to PTSD in teens and young adults who are pregnant or have had a baby in the last year. The study will also explore if it is possible to gather enough information on measurements like heart rate and sleep patterns with smart watches in the same population, to look at brain patterns before and after the therapy, and to see if WET can improve emotions, functioning, and relationships in pregnant and post-partum individuals. Prior to initiating the course of WET, participants will undergo screening procedures to evaluate eligibility. Those eligible will complete 5 sessions of written exposure therapy, one session per week and biomarker data will be collected via a wearable device. Participants will also undergo optional electroencephalography (EEG) as well as self-report and clinician-rated assessments. Follow-up visits will be conducted at 4, 8 and 12 weeks post-baseline (post-treatment for WET), with weekly assessments. The baseline visit must be done in-person in order to set up the smart watch. If participants choose to undergo electroencephalography, they will be required to come in-person for the procedure.

Registry
clinicaltrials.gov
Start Date
March 26, 2025
End Date
August 31, 2026
Last Updated
last year
Study Type
Interventional
Study Design
Single Group
Sex
Female

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Nabila Haque

Resident-Psychiatry

University of Texas Southwestern Medical Center

Eligibility Criteria

Inclusion Criteria

  • Stated willingness to comply with all study procedures and availability for the duration of the study
  • Have been referred by a clinician to the study or receiving standard of care treatment for pregnancy or post-partum follow-up
  • Aged 15-24 at time of screening
  • Either have Gestational age \>12 weeks or be \<1 year postpartum at time of screening
  • Able and willing to provide informed consent if 18 years of age or above or the legal guardian must be able and willing to provide informed consent if participant is less than 18 years of age and participant willing and able to provide assent if less than 18 years of age
  • Able to read, write and speak in English and Spanish; if the participant is under age 18, parents must be able to understand spoken or written English or Spanish.
  • Have the ability to complete clinical evaluations and self-report measures.
  • Meet diagnostic or subthreshold criteria for PTSD.

Exclusion Criteria

  • Have any condition for which, in the opinion of the investigator or designee, study participation would not be in their best interest (including but not limited to cognitive impairment, unstable general medical condition, intoxication, active psychosis) or that could prevent, limit, or confound the protocol-specified assessments.
  • Have current mania, hypomania, or psychosis
  • Be at serious suicidal risk that cannot be managed in the outpatient setting
  • Pervasive or intellectual developmental disorder requiring substantial or very substantial support.
  • Currently receiving or having received course of exposure-based therapy (e.g. WET, PE, CPT, or TF-CBT) in the past six months

Outcomes

Primary Outcomes

Feasibility of Written Exposure Therapy

Time Frame: From enrollment to study exit visit at week 12

Feasibility will be assessed based on recruitment, retention and treatment adherence rates. Acceptability will be evaluated through participant feedback, including satisfaction with the intervention and willingness to engage in treatment. The primary outcome will be the percentage of participants who complete treatment within 4 weeks, for a 12-week study period. We expect at least 70% of participants will be able to complete treatment within 4 weeks.

Secondary Outcomes

  • Changes in PTSD Symptom Severity Assessed by the Clinician Administered Scale for PTSD (CAPS-5)(From enrollment to study exit visit at week 12)
  • Changes in PTSD Symptoms Assessed by the PTSD Checklist for DSM-5(From enrollment to study exit visit at week 12)
  • Change in Sleep Quality Assessed by the Pittsburgh Sleep Quality Index (PSQI)(From enrollment to study exit visit at week 12)
  • Changes in Emotional Regulation Assessed by the Difficulties in Emotion Regulation Scale (DERS-16)(From enrollment to study exit visit at week 12)
  • Changes in Anxiety Assessed by the Perinatal Anxiety Screening Scale (PASS)(From enrollment to study exit visit at week 12)

Study Sites (1)

Loading locations...

Similar Trials